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C A S E  S E R I E S
Pharmacological Intervention in Children with 
Autism Spectrum Disorder with Standard Supportive 
Therapies Significantly Improves Core Signs and 
Symptoms: A Single-Center, Retrospective Case 
Series
This article was published in the following Dove Press journal: 
Neuropsychiatric Disease and Treatment
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Purpose: Autism spectrum disorder (ASD) is a debilitating neurodevelopmental disorder with 
high heterogeneity and no clear common cause. Several drugs, in particular risperidone and 
aripiprazole, are used to treat comorbid challenging behaviors in children with ASD. Treatment 
with risperidone and aripiprazole is currently recommended by the Food and Drug 
Administration (FDA) in the USA for children aged 5 and 6 years and older, respectively. 
Here, we investigated the use of these medications in younger patients aged 4 years and older.
Patients and Methods: This retrospective case series included 18 children (mean age, 5.7 
years) with ASD treated at the Kids Neuro Clinic and Rehab Center in Dubai. These patients 
began treatment with risperidone or aripiprazole at the age of 4 years and older, and all 
patients presented with comorbid challenging behaviors that warranted pharmacological 
intervention with either risperidone or aripiprazole.
Results: All 18 children showed objective improvement in their ASD core signs and symptoms. 
Significant improvement was observed in 44% of the cases, and complete resolution (minimal-to 
-no-symptoms) was observed in 56% of the cases as per the Childhood Autism Rating Scale 
2-Standard Test (CARS2-ST) and the Clinical Global Impression (CGI) scales.
Conclusion: Our findings indicate that the chronic administration of antipsychotic medica-
tions with or without ADHD medications is well tolerated and efficacious in the treatment of 
ASD core and comorbid symptoms in younger children when combined with standard 
supportive therapies. This is the first report to suggest a treatment approach that may 
completely resolve the core signs and symptoms of ASD. While the reported outcomes 
indicate significant improvement to complete resolution of ASD, pharmacological interven-
tion should continue to be considered as part of a multi-component intervention in combina-
tion with standard supportive therapies. Furthermore, the findings support the critical need 
for double-blind, placebo-controlled studies to validate the outcomes.
Keywords: risperidone, aripiprazole, antipsychotic, comorbid challenging behaviors
Plain Language Summary
ASD is a chronic neurodevelopmental disorder that is increasing in prevalence worldwide.
There are no FDA-approved medications to treat the core symptoms 
even though ASD shares many signs and symptoms with other neuropsychiatric 
diseases.
Correspondence: Hamza A Alsayouf  
Kids Neuro Clinic and Rehab Center, 
Dubai Healthcare City, Dubai, United 
Arab Emirates  
Tel +97 145570326  
Email leeamra1000@gmail.com
submit your manuscript | www.dovepress.com Neuropsychiatric Disease and Treatment 2020:16 2779–2794                                            2779
http://doi.org/10.2147/NDT.S277294 
DovePress © 2020 Alsayouf et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the 
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Neuropsychiatric Disease and Treatment                                              Dovepress
open access to scientific and medical research
Open Access Full Text Article
 
N
eu
ro
ps
yc
hi
at
ric
 D
is
ea
se
 a
nd
 T
re
at
m
en
t d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
16
3.
8.
76
 o
n 
22
-N
ov
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
FDA-approved pharmacological therapies are currently only 
indicated for the treatment of comorbid irritability and severe 
behavioral issues in children with ASD aged 5 years and older.
In this study, antipsychotic medications, with or without 
ADHD medications, were found to significantly improve ASD 
core symptoms when used in combination with standard suppor-
tive therapies.
We observed complete resolution of core ASD symptoms in 
56% of our patient cohort, which is unprecedented in the medical 
literature.
Dose optimization for each patient and chronic use are key to 
resolving core signs and symptoms.
The potential benefits and risks must be weighed on a case- 
by-case basis when considering further optimization of 
medications to target core symptoms in children with ASD and 
comorbid behavioral issues.
Introduction
Autism spectrum disorder (ASD) is a complex neurodeve-
lopmental disorder with high heterogeneity.1 In 2013, the 
Diagnostic and Statistical Manual of Mental Disorders, 
fifth edition (DSM-5), consolidated the four previously 
separate categories of autism under the single umbrella 
of “autism spectrum disorder.”1 These categories were 
autistic disorder, Asperger’s syndrome, childhood disinte-
grative disorder, and pervasive developmental disorder not 
otherwise specified.1,2 While the symptoms of ASD can 
manifest before 2 years of age, they usually become more 
apparent between 2 and 3 years of age.1,3 Patients with 
ASD are all unique in their presentation; however, the 
disorder is characterized by core symptoms that include 
impairments in social interaction and communication, as 
well as the presence of restricted and repetitive behaviors.1 
These symptoms are universal regardless of culture, race, 
ethnicity, or socioeconomic group.1 All children with ASD 
experience difficulty in developing social, speech, and 
behavioral skills. Therefore, early intervention with beha-
vioral therapy affords these children with the best oppor-
tunity to support healthy development and to deliver 
benefits across their life span.2 Pharmacological interven-
tions, where needed, are used as an adjunct to support 
patients’ function in their daily activities and to treat 
comorbid irritability and difficult behaviors.4,5
ASD impairs social skills and autonomy to a variable 
and sometimes severe extent. A longitudinal study over 40 
years has shown general improvement in symptoms in 
young adulthood but poor outcomes in later adulthood.6 
Although core domains may improve across the life span, 
some symptom subdomains, such as limited interests or 
facial expressions, may remain unchanged over time.7,8 
The impact of these long-term deficits on functioning is 
severe, with manifestations that can become increasingly 
complex later in life.9 In 2018, the Centers for Disease 
Control and Prevention (CDC) in the USA determined that 
approximately 1 in 59 children is diagnosed with ASD (1 
in 37 boys and 1 in 151 girls), with increasing 
prevalence year after year.10
Unfortunately, the current evidence-based pharmacolo-
gical treatment approach for ASD is limited to the treat-
ment and control of comorbid challenging behaviors 
only.11 Risperidone and aripiprazole were approved by 
the FDA in 2006 and 2009, respectively, to treat irritability 
associated with ASD.12,13 The recommended age to initi-
ate treatment with these medications is 5 years and above 
for risperidone and 6 years and above for aripiprazole. In 
randomized controlled trials, risperidone and aripiprazole 
have been found to improve irritability and agitation in 
children with ASD.14,15 The majority of children with 
ASD show improvements in challenging comorbid beha-
viors such as irritability, agitation, aggression, self-injury, 
and disruptive behaviors when using these medications.16 
Both drugs are classified as atypical antipsychotics, and 
this class of medication can potentially cause significant 
side effects such as sedation, weight gain, and metabolic 
disturbances; therefore, close follow-up and monitoring by 
a physician with special expertise are required when using 
these medications.17 To mitigate medication-induced 
weight gain, metformin can be prescribed if needed.17,18 
Several medications typically used to treat children with 
attention-deficit hyperactivity disorder (ADHD), including 
methylphenidate, atomoxetine, guanfacine, and bupropion, 
have been reported to also improve hyperactivity and 
attention symptoms in children with ASD.19–22
In this retrospective report, we present our single- 
center experience in treating 18 children with ASD and 
comorbid behavioral issues. These children were treated 
from the age of 4 years and older with risperidone or 
aripiprazole, either with or without atomoxetine or methyl-
phenidate, combined with standard supportive therapies. 
A significant clinical and statistical improvement in the 
patients’ core signs and symptoms, in addition to improve-
ments in their behavioral issues, was observed as per the 
Childhood Autism Rating Scale 2-Standard Test (CARS2- 
ST) and the Clinical Global Impression (CGI) scales.23,24 
The Clinical Global Impression-Severity (CGI-S) and 
CARS2-ST scale were performed at baseline, and serial 
Clinical Global Impression-Improvement (CGI-I) scores 
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were obtained to monitor improvement. Once a patient 
attained a CGI-I score of 1 or 2 we repeated the CGI-S 
and CARS2-ST to further confirm improvement, in addi-
tion to serial clinical evaluations and follow-up.
Patients and Methods
Patients
This is a retrospective case series report of all patients, 
aged 4 years or older, who were diagnosed with autism 
spectrum disorder and comorbid behavioral issues and 
treated at our center (Kids Neuro Clinic and Rehab 
Center, Dubai) from 2017 to 2020, and for whom 
informed consent was obtained from the parents or legal 
guardians to participate in this study. The cohort com-
prised 18 children in total. The children’s parents and 
legal guardians were duly notified of the off-label use 
and potential side effects of the antipsychotic medications 
used in this study. The data collected for each patient 
included: age at presentation, age of initiation of the first 
medication, medications used, starting dose, time to reach 
the maximum dose, current medications, medication side 
effects, analyses performed, initial signs and symptoms, 
initial formal diagnosis as per the DSM-5 criteria and 
CARS2-ST, baseline CGI-S score before starting medica-
tions, Clinical Global Impression-Improvement (CGI-I) 
score, and their repeat CARS2-ST as per their last visit 
to our clinic.
To supplement the CGI-I scale, we also used the CGI-S 
score in addition to CARS2-ST at baseline against which 
we marked each patient’s severity prior to starting medica-
tions. Condition severity was scored on the following 
seven-point CGI-S scale: 1 = normal, not at all ill; 2 = 
borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 
= markedly ill; 6 = severely ill; 7 = among the most 
extremely ill patients.23
CGI-I is scored on a seven-point scale that compares 
the patient’s current condition to their baseline condition 
before treatment initiation: 1 = very much improved since 
the initiation of treatment; 2 = much improved; 3 = mini-
mally improved; 4 = no change from baseline (the initia-
tion of treatment); 5 = minimally worse; 6 = much worse; 
7 = very much worse since the initiation of treatment.23
CARS2-ST can be used for children aged 2 years and 
older and classifies patients into three ASD severity groups 
based on a 15-category scoring system: minimal-to-no 
symptoms of ASD, mild-to-moderate symptoms of ASD, 
and severe symptoms of ASD.5,24,25
This retrospective observational case series was 
approved by an independent Institutional Review Board 
(IRB), the Pearl IRB Committee, which is fully accredited 
by the Association for the Accreditation of Human 
Research Protection Program (AAHRPP; approval no. 20- 
KNRC-101). This study was also approved locally by the 
Dubai Healthcare City Regulatory Ethics Committee 
(DHCR; approval no. KNCRC-01)
Diagnosis
When a patient with signs and symptoms suggestive of 
ASD presented at our clinic, we performed a thorough 
history and physical examination. In addition, we per-
formed an electroencephalogram (EEG) with a sleep sam-
ple to evaluate for electrical status epilepticus in sleep or 
epileptic encephalopathy, as well as an auditory brainstem 
response (ABR) test to assess for hearing loss. These tests 
were conducted to exclude potentially treatable 
conditions requiring different treatment approaches.26–29 
Pharmacological treatment was recommended if the indi-
vidual had a normal ABR, normal EEG, no findings sug-
gestive of a genetic disorder (such as dysmorphic features, 
a family history of genetic disorders, or an abnormal 
genetic test), no global developmental delay, and 
a confirmed ASD diagnosis as per the DSM-5 criteria 
and CARS2-ST, and a CGI-S score ≥ 4 with comorbid 
behavioral issues. In each case, the diagnosis was obtained 
by both a pediatric neurologist and a clinical psychologist 
following a multidisciplinary assessment and diagnostic 
approach. A flowchart of the diagnosis and medication 
schedule is depicted in Figure 1.
Treatment
Based on previous safety and efficacy studies recommend-
ing atypical antipsychotics for the treatment of the comor-
bid behavioral symptoms of ASD, patients were prescribed 
either risperidone or aripiprazole.12,13 Risperidone treatment 
was usually initiated with 0.25 mg orally at night, and this 
dose was increased gradually every 1 to 2 weeks until 
reaching either a maximum dose of 2 mg in the morning 
and 0.5 mg at night or the maximum dose tolerated by each 
patient within these limits (see Table 1 for each patient’s 
dosing schedule). This regimen was adhered to as long as 
the patient showed improvement with each dose increment 
and no side effects. This approach was followed for 8/18 
(44%) cases (cases 1, 6, 7, 9, 10, 14, 17, and 18). 
Aripiprazole was started at 1 mg at night, and this dose 
was increased gradually every 1 to 2 weeks until reaching 
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a maximum dose of 15 mg at night or the maximum 
tolerated dose for the patient (Table 1). This regimen was 
adhered to as long as an improvement was observed with no 
side effects. This approach was followed for 10/18 (56%) 
cases (cases 2, 3, 4, 5, 8, 11, 12, 13, 15, and 16). The 
clinical data for all of the patients are provided in Table 1.
no
Signs and symptoms suggestive of ASD
yes
After family counselling, start patient on risperidone or 
aripiprazole and slowly increase dose 
Patient shows clinical improvement as per CGI-I scale 
with dose increment 
Continue to increase risperidone or aripiprazole to 
maximum dose or maximum tolerated dose 
yes
Switch risperidone to aripiprazole or 
vice versa and increase dose slowly
Clinical improvement?
Stop medication
Refer for audiology/ENT if 
hearing loss is suspected
Treat for ESES or epileptic 
encephalopathy if EEG is 
consistent with that approach
Consider genetic testing and 
referral to geneticist
yes
No history or physical findings suggestive of genetic disease or global 
developmental delay AND normal EEG with sleep sample and normal ABR
Diagnosis: DSM-5 criteria, CARS2-ST, & CGI-S ≥4
yes
Patient attains CGI-I score of 1 with no excessive 
weight gain 
yes
Continue medication for at least 6 months after 
complete resolution of ASD AND total of 20 months 
before any slow trial wean
Any signs of ASD recurrence, ADHD, or comorbid 
symptoms while weaning
no yes
Continue to wean 
until completely 
off medication
Keep on minimum dose to fully 
control signs and symptoms and 
try to wean again in 6–12 
months
Add methylphenidate or atomoxetine and increase 
dose slowly to maximum tolerated dose
Switch patient to 
atomoxetine if on 
methylphenidate or 
vice versa
no
Does patient tolerate medication well?
Patient attains CGI-I score of 1 with no excessive 
weight gain
Add atomoxetine if on 
methylphenidate or 
vice versa
yes no
no
no
Patient tolerates new medication with 
good weight control and CGI-I 1 
no
Stop alternative or added 
medications.
If patient continues to have 
weight gain, consider 
decreasing risperidone or 
aripiprazole dose to 
minimum effective dose.
If patient improved but 
plateaued at CGI-I 2, 
continue medication with 
regular follow up for side 
effects.
Patient tolerates added medication with good weight 
control and maintains a CGI-I score of 1
Continue medication until complete resolution of ASD 
symptoms for a total of at least 20 months, start 
weaning off risperidone or aripiprazole first
Any signs of ASD recurrence, ADHD, or comorbid conditions
no yes
Wean until completely off 
risperidone or aripiprazole, then 
wean off methylphenidate or 
atomoxetine
Keep on minimum 
dose and try to wean 
again in 6–12 months
If there are any signs of ASD recurrence or comorbid 
conditions while weaning methylphenidate or atomoxetine
yes
yes
Figure 1 Flowchart of the diagnosis and medication schedule.
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When a patient tolerated risperidone or aripiprazole 
with no side effects and showed progressive improvement 
to a CGI-I score of 1 or 2, the child was continued on that 
medication. If the CGI-I score plateaued at 2 or higher, or 
the patient started to gain excessive weight and still exhib-
ited hyperactivity or an inadequate attention span, methyl-
phenidate or atomoxetine was added in an effort to 
augment improvement to a CGI-I score of 1, improve 
their attention span, and control excessive weight gain 
(these classes of medication are known to suppress appe-
tite). All children with progressive weight gain were also 
referred to a nutritionist since progressive weight gain can 
cause serious health issues and may affect compliance 
with therapy and lead to the premature tapering of the 
medication.
Methylphenidate was usually added at 2.5 mg in the 
morning and increased gradually to a maximum dose of 
20 mg in the morning or less as tolerated. Atomoxetine 
was usually added at 10 mg at night and increased gradu-
ally to a maximum dose of 60 mg at night or less as 
tolerated, as long as no side effects were observed and 
an improvement was seen with each dose increment (Table 
1). Once a patient reached a CGI-I score of 1 and a repeat 
CARS2-ST score of minimal-to-no symptoms of ASD, we 
continued the medications for an additional 6 months 
before trying to wean the child very slowly off the med-
ications (Figure 1 describes the process used for weaning).
Before the initiation of therapy, a complete blood 
count, kidney function test, and lipid panel were per-
formed, and the levels of electrolytes, liver enzymes, 
hemoglobin A1c, and prolactin were determined to pro-
vide a baseline for monitoring any metabolic side effects 
of the antipsychotic medications.30–34 The tests were 
repeated 3 to 6 months after initiating medication, fol-
lowed by subsequent yearly checkups. Similarly, cardiac 
evaluations to monitor for any adverse medication effects, 
including an echocardiogram and electrocardiogram, were 
obtained by a fully trained pediatric cardiologist for half of 
the patients 9/18 (50%) when the maximum dose was 
reached or earlier if clinically indicated.35–37 Serial mea-
surements of weight, body mass index (BMI), height, and 
vital signs were obtained for each patient at every office 
visit.
The initial presenting and current signs and symptoms 
of each patient, initial and current CARS2-ST scores, 
initial diagnosis as per the DSM-5 criteria, baseline CGI- 
S score, and current CGI-S and CGI-I scores are described 
in Supplementary Table S1.1
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All patients were strongly advised to continue the 
standard supportive therapies, such as applied behavior 
analysis (ABA) therapy, speech therapy, and occupational 
therapy. Where a family could not afford these therapies, 
the parents and caregivers were provided practical support 
and guidance as per our center’s practice. All parents and 
caregivers were strongly encouraged to maximize their 
child’s opportunity for social interactions by attending 
a daycare, nursery, or playgroups, as well as strongly 
advised to limit their child’s screen time where applicable.
Statistical Analysis
The statistical significance of the differences between the 
mean pre- and post-treatment CGI-S and CARS2-ST 
scores was determined with the Wilcoxon signed-rank 
test. A P-value < 0.05 was considered statistically signifi-
cant. Data were analyzed using the VassarStats online suite 
of statistical tools (www.vassarstats.net).
Results
In total, 18 cases of ASD were included in this study, 
comprising 14 males and 4 females with a 3.5:1 male-to- 
female ratio. The age of the patients at presentation ranged 
from 4 to 10 years (mean age 5.7 years). The duration of 
treatment ranged from 6 to 43 months (mean 18.3 
months). Eight patients (44%) were started on risperidone 
and 10 patients (56%) were started on aripiprazole. 
Efficacy of treatment was based on the changes in the 
CGI-I score from baseline, the repeat CARS2-ST score, 
family reports, and clinical observations of the treating 
physician.
In total, 10/18 (56%) patients attained a CGI-I score of 
1 and had minimal-to-no symptoms of ASD (ie, complete 
resolution of ASD symptoms) when reassessed with the 
CARS2-ST, while the remaining 8/18 (44%) patients 
attained a CGI-I of 2 and a reassessment using CARS2- 
ST showed significant improvement from their baseline 
score. The differences in the mean CGI-S and CARS2- 
ST scores pre- and post-treatment in our cohort were 
statistically significant (Z = 3.71, P < 0.001 for both) 
using the Wilcoxon signed-ranked test, with pre- and post- 
treatment median values of 5 and 1 for CGI-S, respec-
tively, and 35 and 22 for CARS2-ST, respectively.
Among the eight patients who were treated with risper-
idone with or without methylphenidate or atomoxetine in 
this case series, 5/8 patients (62%) achieved a CGI-I score 
of 1 and minimal-to-no-symptoms of ASD when reas-
sessed on the CARS2-ST (cases 1, 9, 10, 14, and 18). 
The other 3/8 patients (38%) achieved a CGI-I score of 2 
and their repeat CARS2-ST showed significant improve-
ment from baseline (cases 6, 7, and 17). Two of the eight 
patients (25%) continued with risperidone only and did not 
require any adjunct therapy for attention issues (cases 9 
and 14).
Among the 10 patients who were treated with aripipra-
zole with or without atomoxetine or methylphenidate in 
this case series, 6/10 patients (60%) achieved a CGI-I 
score of 1 with a normal repeat CARS2-ST (cases 2, 3, 
4, 5, 8, and 13), and 4/10 patients (40%) achieved a CGI-I 
score of 2 and their repeat CARS2-ST showed significant 
improvement from baseline (cases 11, 12, 15, and 16). The 
remaining 3/10 patients (30%) did not require any adjunct 
therapy to aid attention (cases 3, 12, and 13).
Three patients (cases 2, 16, and 17) showed clear 
improvement on monotherapy with risperidone or aripi-
prazole to a CGI-I score of 1 or 2 but started to exhibit 
excessive weight gain (BMI > 25) with attention deficit; 
therefore, atomoxetine or methylphenidate was added. One 
patient (case 4) continued to be inattentive on aripiprazole 
15 mg and atomoxetine 40 mg at night; therefore, long- 
acting methylphenidate was added in the morning and the 
dose was increased to 36 mg. This combination improved 
his attention greatly and further improved his CGI-I score 
from 2 to 1 with minimal-to-no symptoms of ASD on his 
repeat CARS2-ST. One patient (case 16) started to gain 
excessive weight with no clear improvement with risper-
idone dose increments; therefore, he was switched to ari-
piprazole with clear improvement. Two patients (cases 1 
and 11) did not tolerate or did not show clear clinical 
improvement with atomoxetine as an adjunct therapy and 
were switched to methylphenidate with superior results. 
Three patients (cases 6, 15, and 17) who did not show 
clear improvement on methylphenidate as an adjunct ther-
apy or who started to be irritable were switched to ato-
moxetine with clear improvement. One patient attained 
a CGI-I score of 1 and had minimal-to-no-symptoms of 
ASD when reassessed on the CARS2-ST, and he is cur-
rently off all medications after being on risperidone for 
a total of 37 months (case 14). One patient is on 
a maintenance dose only to control symptoms of anxiety 
and self-talking, currently attends regular school, and had 
minimal-to-no-symptoms of ASD when reassessed on the 
CARS2-ST (case 5). All medication regimens are pre-
sented in Table 1.
One family stopped risperidone prematurely due to 
concerns about medication side effects, and this resulted 
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in a clear regression of the patient (case 9) to his original 
status. Risperidone was then restarted. The parents of one 
patient (case 14) ran out of medication 20 months after 
starting risperidone and 4 months after reaching the full 
dose of 2 mg in the morning and 0.5 mg at night. The 
family noted that during the 4 weeks that he was off 
medication, the child became hyperactive again and inat-
tentive but did not relapse to his initial ASD symptoms. 
That he did not completely relapse may be explained by 
the fact that he had already been on risperidone for 20 
months, in comparison with case 13, who had only been 
on risperidone for 5 months. Of note, one patient (case 5) 
completely regressed when she was switched to risperi-
done from aripiprazole when aripiprazole was out of stock, 
and she was, therefore, placed back on aripiprazole as 
soon as it became available again. Another patient (case 
18) was already on risperidone and atomoxetine for almost 
a year when she presented to us but was still showing 
signs and symptoms of ASD. Once the doses were opti-
mized, she attained a CGI-I score of 1 and had minimal-to- 
no-symptoms of ASD when reassessed on the CARS2-ST.
Laboratory results for our patients (complete blood 
count, electrolytes, liver enzymes, kidney function test, 
lipid panel, and hemoglobin A1c) were all within normal 
limits for their age. Three patients (17%; cases 9, 10, and 
14) developed asymptomatically elevated prolactin levels 
and were treated conservatively as per the recommenda-
tions of a pediatric endocrinologist. Cardiac monitoring 
did not reveal any adverse effects. Some families were 
unable to afford cardiac evaluation or unwilling to undergo 
it, in which case the patients were monitored clinically for 
any signs or symptoms of cardiac issues, but none showed 
any adverse cardiac effects.
Discussion
Altered neuronal connectivity and plasticity in the brain 
cortex are reported to be the underlying cause for the signs 
and symptoms observed in ASD patients.38–41 In mice 
with ASD, the prefrontal cortex appears to be the main 
site of brain pathology.42–45 Aman et al reported 
a considerable improvement in irritability and maladaptive 
behavior in comparison to the baseline, including core 
symptoms associated with ASD, in ASD patients who 
had been treated with risperidone for an average of 21 
months.46 Recent studies in mice have shown that the 
chronic administration of risperidone or aripiprazole 
improves valproic acid-induced social interaction deficits 
and recognition memory impairment, with reductions 
observed in dendritic spine density in the prefrontal cortex 
and hippocampus.47 In addition, methylphenidate and ato-
moxetine were both found to improve valproic acid- 
induced social deficits and recognition memory impair-
ment in mice.48
The financial and social burden of ASD is huge and 
expected to rise substantially in the coming years.10 For 
example, intensive behavioral interventions for children 
with ASD cost from $40,000 to $60,000 per child in the 
USA in 2011.49 The lifelong cost of supporting an indivi-
dual with ASD and intellectual disability is estimated to be 
$2.4 million in the USA and £1.5 million ($2.2 million) in 
the UK.50 Residential care or supportive living accommo-
dation during adulthood and individual productivity loss 
both contribute to these high costs.50 Caring for Americans 
with ASD cost society a staggering $268 billion in 2015, 
a number that has increased more than six-fold since 2006 
and is expected to rise to $461 billion by 2025 in the 
absence of more effective interventions and support across 
patients’ life spans.10,51 Therefore, finding a successful 
treatment for ASD is a global necessity.
For this case series, children who presented with ASD 
and comorbid challenging behaviors at our center were 
started on the antipsychotics risperidone or aripiprazole 
provided their parents or legal guardians agreed with the 
treatment plan and understood the off-label use of such 
medications. We titrated medication doses to also target 
core symptoms and not just control challenging behaviors. 
We combined two proven therapeutic approaches, namely 
non-biological (eg, ABA therapy) and biological therapies 
(risperidone and aripiprazole), to treat children with ASD 
in a region where the vast majority cannot afford full 
supportive therapies. We added ADHD medications as 
needed to further augment attention as attention is crucial 
in the learning process. This intervention approach is 
based on our initial observations that these medications 
improved many aspects of ASD symptoms when used to 
control comorbid behavior as indicated by the FDA. We 
noted that treating difficult comorbid behavior, anxiety, 
poor attention, and hyperactivity made ASD patients 
a lot more responsive and receptive to supportive thera-
pies. In addition, many previous studies and reports sup-
port the use of these medications in young children with 
ASD.14–17,19,20 Several studies have shown improvements 
in the core symptoms of children with ASD when using 
risperidone or aripiprazole, including language impair-
ment, maladaptive behaviors, social withdrawal, stereo-
typy, sensory motor issues, inappropriate speech, and 
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ADHD.52–58 Troost et al, in their placebo discontinuation 
study, reported that risperidone helped prevent relapses in 
problem behaviors in children with ASD when used for 6 
months, and the authors concluded that these results pro-
vide a rationale for the continued use of risperidone 
beyond 6 months with close observation for weight gain.59
Here, the medication doses were slowly increased to 
the maximum dose tolerated and this regimen was main-
tained as long as the patient continued to show improve-
ment and the maximum allowed dose had not been 
reached. If the patient did not respond to risperidone, the 
patient was shifted to aripiprazole or vice versa. Patients 
who responded initially but then plateaued over subse-
quent dose increments were supplemented with atomoxe-
tine or methylphenidate to help increase attention, control 
hyperactivity, and attain further improvement. Patients 
who continued to improve with risperidone or aripiprazole 
increments but started to experience side effects, such as 
excessive weight gain along with attention deficit and/or 
hyperactivity, were also supplemented with atomoxetine or 
methylphenidate to control their weight and further 
improve their attention span. Our goal was to achieve 
a low CGI-I score with minimal-to-no-symptoms of ASD 
as per the CARS2-ST and clinical evaluation.
We used the DSM-5 criteria and CARS2-ST to confirm 
the diagnosis of ASD. The CGI scale and CARS2-ST were 
used to measure baseline severity and to monitor improve-
ment. The American Academy of Child and Adolescent 
Psychiatry (AACAP), in its 2014 ASD practice para-
meters, emphasized that the most important diagnostic 
step is clinical diagnosis based on careful consideration 
of the DSM-5 criteria.4 These guidelines further empha-
size that while there are many assessment instruments for 
ASD, including the childhood autism rating scale (CARS) 
and the autism diagnostic observation scale (ADOS) 
among others, these instruments, if needed, should only 
supplement and not replace informed clinical judgment 
based on the DSM-5 criteria. The American Academy of 
Pediatrics (AAP), in its latest ASD clinical report pub-
lished in 2020, emphasized the importance of using the 
DSM-5 criteria and definitions for the clinical diagnosis of 
ASD.5 Severity ratings of DSM-5 criteria do not provide 
a quantifiable score and are based on the extent of the 
patient’s social communication impairments, their 
restricted and repetitive patterns of behavior, and the resul-
tant level of care the individual requires; thus, these ratings 
often reflect the impact of cognitive limitations.5,60 In 
contrast, the CGI-I scale offers an objective, readily 
understood, and practical measurement tool that can be 
easily applied even in a very busy clinical setting. It has 
two main features that make it suitable for ASD patients 
and treatment trials: there is scope for cross-comparison 
with the many other trials in which the CGI-I rating scale 
has been used in psychiatry, and it reflects general severity 
and clinical improvement even in small ASD studies, 
especially when combined with a standard ASD test like 
CARS2-ST.60,61 Therefore, in addition to clinical diagno-
sis based on the DSM-5 criteria, which also provides 
a severity scale, we included CARS2-ST and the CGI 
scales to try to maximize sensitivity and specificity in 
diagnosis and when monitoring for improvement among 
our patients.5,7,60 Diagnosis in each case was made by 
a team comprising both a pediatric neurologist and clinical 
psychologist.
In this case series, while risperidone or aripiprazole 
was started at an earlier age than that recommended by 
the FDA to primarily control behavioral issues, the off- 
label use of risperidone, aripiprazole, and other psycho-
tropic medications is well described in common practice 
with a trend of increasing use in recent years, especially in 
preschool children with ASD.62–68 Treating our patients 
with early and chronic administration of risperidone or 
aripiprazole along with standard supportive therapies, sup-
plemented with methylphenidate or atomoxetine as needed 
to augment attention, resulted in marked and statistically 
significant clinical improvement with minimal-to-no- 
symptoms (resolution of symptoms) of ASD in 56% of 
these patients as per the CGI-S scale, CARS2-ST, and 
clinical evaluation.
This is a single-center case series of children with ASD 
who were treated successfully with the antipsychotic drugs 
risperidone and aripiprazole in combination with atomoxe-
tine or methylphenidate along with standard supportive 
therapies. These medications have been available on the 
market for over a decade and have been used to treat 
psychiatric disorders that share many features with 
ASD.69,70 Recent meta-analyses concluded that patients 
with ASD have a high burden of comorbid neuropsychiatric 
disorders such as anxiety disorders, depressive disorders, 
bipolar and mood disorders, schizophrenia spectrum, suici-
dal behavior disorders, attention-deficit/hyperactivity disor-
der, as well as disruptive, impulse-control, and conduct 
disorders and may share underlying brain circuit disruption 
or pathology.69,70 The improvements in symptoms in our 
patient cohort are likely due to the following: initiating 
risperidone or aripiprazole as soon as a diagnosis was 
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made and as young as 4 years to control challenging beha-
vior that can be a major barrier for learning, prescribing 
medications to control challenging behavior and target the 
core symptoms under the assumption that all ASD core 
symptoms are neuropsychiatric in nature and need to be 
treated the same way, and slowly increasing the medication 
doses to the maximum tolerated or highest dose allowed to 
achieve significant clinical improvement with an individua-
lized treatment plan. These medications need to be used for 
many months to result in minimal-to-no-symptoms of ASD 
signs and symptoms, and treatment requires combining 
antipsychotic drugs with medications used for attention 
deficit hyperactivity as needed, to augment attention and 
control hyperactivity. This must be performed in a manner 
that is tailored to each patient’s response, as attention plays 
a critical role in the learning process. Unfortunately, all 
double-blind, placebo-controlled studies performed to date 
on ASD were of short duration, used medications to pri-
marily control challenging behaviors in children with ASD, 
did not combine antipsychotic medications with ADHD 
medications, and did not include cross-over design for non- 
responders.14,15,56,71–78
The main side effects noted were weight gain, sedation, 
drooling, and irritability. Sedation and drooling were noted 
mainly when first initiating the medications, were mild in 
nature, and disappeared with continuation of the medica-
tions. This could be related to the very slow titration 
schedule we used for our patients. Weight gain was exces-
sive, uncontrollable (BMI > 25), and required further 
intervention in only five patients (17%).
A major challenge we faced in our approach was to 
convince the families to start or continue using the medi-
cations once they were duly informed about the side 
effects of the medications and their FDA-approved uses.
The findings of this case series are limited because of 
the small sample size and retrospective nature of the data 
collection. These factors might have caused an inherent 
bias in the results. Cardiac evaluations were not performed 
for all patients, mainly because of affordability issues or 
the families being unwilling.
Conclusions
Our study showed clinically and statistically significant 
improvement of ASD patients’ core signs and symptoms as 
per the CGI scales and CARS2-ST with early and chronic 
administration of risperidone or aripiprazole, with or without 
ADHD medications, and combined with standard supportive 
therapy. Our findings suggest that a notable proportion of 
patients with ASD can be successfully treated and potentially 
cured this way. Early intervention with behavioral therapy 
and pharmacological medications provide the best opportu-
nity to support normal development in children with ASD. 
No one medication works for all children, and a trial of other 
antipsychotic medications should be used if a patient fails to 
respond to the first medication tried. While reported out-
comes indicate significant improvement in the core signs 
and symptoms of ASD, pharmacological intervention should 
continue to be considered as part of a multi-component 
intervention in combination with standard supportive thera-
pies. The potential benefits and risks must be weighed on 
a case-by-case basis when considering the use of medications 
to target core symptoms in children with ASD. Double-blind, 
placebo-controlled studies should be conducted to verify the 
findings of our study. Finding an effective treatment for ASD 
is of utmost importance because of its increasing prevalence, 
its poorly understood causes and pathology, and its devastat-
ing consequences.
Data Sharing Statement
The data supporting the findings of this study are available 
from the corresponding author upon reasonable request.
Ethics Approval and Informed 
Consent
This retrospective observational case series was deemed by 
an independent Institutional Review Board (IRB), the Pearl 
IRB Committee, which is fully accredited by the Association 
for the Accreditation of Human Research Protection 
Program (AAHRPP), as exempt according to FDA 21 CFR 
56.104 and 45CFR46.104(b)(4): (4) Secondary Research 
Uses of Data or Specimens on 06/01/2020 (approval no. 20- 
KNRC-101). This study was also approved locally by the 
Dubai Healthcare City Regulatory Ethics Committee 
(DHCR; approval no. KNCRC-01). Informed consent to 
participate in this study and publish the case details was 
obtained from the parents or legal guardians of all patients.
Author Contributions
All authors made a significant contribution to the work 
reported, whether that is in the conception, study design, 
execution, acquisition of data, analysis and interpretation, 
or in all these areas; took part in drafting, revising or 
critically reviewing the article; gave final approval of the 
version to be published; have agreed on the journal to 
Neuropsychiatric Disease and Treatment 2020:16                                                                       submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                       
2791
Dovepress                                                                                                                                                        Alsayouf et al
 
N
eu
ro
ps
yc
hi
at
ric
 D
is
ea
se
 a
nd
 T
re
at
m
en
t d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
16
3.
8.
76
 o
n 
22
-N
ov
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
which the article has been submitted; and agree to be 
accountable for all aspects of the work.
Funding
There is no funding to report.
Disclosure
The authors declare that they have no competing interests.
References
1. American Psychiatric Association. DSM-5 Task Force. Diagnostic 
and Statistical Manual of Mental Disorders: DSM-5. 5th ed. 
Washington, DC: American Psychiatric Association; 2013.
2. Zwaigenbaum L, Bauman ML, Choueiri R, et al. Early intervention 
for children with autism spectrum disorder under 3 years of age: 
recommendations for practice and research. Pediatrics. 2015;136 
(Suppl 1):S60–81. doi:10.1542/peds.2014-3667E
3. Carbone PS, Campbell K, Wilkes J, et al. Primary care autism 
screening and later autism diagnosis. Pediatrics. 2020;146(2): 
e20192314. doi:10.1542/peds.2019-2314
4. Volkmar F, Siegel M, Woodbury-Smith M, King B, McCracken J, 
State M. Practice parameter for the assessment and treatment of 
children and adolescents with autism spectrum disorder. J Am Acad 
Child Adolesc Psychiatry. 2014;53(2):237–257. doi:10.1016/j. 
jaac.2013.10.013
5. Hyman SL, Levy SE, Myers SM. For council on children with 
disabilities, section on developmental and behavioral pediatrics. 
Identification, evaluation, and management of children with autism 
spectrum disorder. Pediatrics. 2020;145(1):e20193447. doi:10.1542/ 
peds.2019-3447
6. Magiati I, Tay XW, Howlin P. Cognitive, language, social and beha-
vioural outcomes in adults with autism spectrum disorders: 
a systematic review of longitudinal follow-up studies in adulthood. 
Clin Psychol Rev. 2014;34(1):73–86. doi:10.1016/j.cpr.2013.11.002
7. Esbensen AJ, Seltzer MM, Lam KS, Bodfish JW. Age-related differ-
ences in restricted repetitive behaviors in autism spectrum disorders. 
J Autism Dev Disord. 2009;39(1):57–66.
8. Bal VH, Kim SH, Fok M, Lord C. Autism spectrum disorder symp-
toms from ages 2 to 19 years: implications for diagnosing adolescents 
and young adults. Autism Res. 2019;12(1):89–99. doi:10.1002/ 
aur.2004
9. Militerni R, Bravaccio C, Falco C, Fico C, Palermo MT. Repetitive 
behaviors in autistic disorder. Eur Child Adolesc Psychiatry. 2002;11 
(5):210–218.
10. Centers for Disease Control. Data & statistics on autism spectrum 
disorder; 2018. Available from: https://www.cdc.gov/ncbddd/autism/ 
data.html. Accessed July 26, 2018.
11. Lord C, Elsabbagh M, Baird G, Veenstra-Vanderweele J. Autism 
spectrum disorder. Lancet. 2018;392(10146):508–520. doi:10.1016/ 
S0140-6736(18)31129-2
12. Food and Drug Administration. Approval for risperdal (risperidone) 
in the treatment of irritability associated with autistic disorder; 2006. 
Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/ 
2 0 0 6 / 0 2 0 2 7 2 O r i g 1 s 0 3 6 , s 0 4 1 , 0 2 0 5 8 8 O r i g 1 s 0 2 4 , s 0 2 8 ,  
s029,21444Orig1s008,s015.pdf. Accessed January 27, 2015.
13. Squibb BM. U.S. Food and Drug Administration approves 
ABILIFY® (aripiprazole) for the treatment of irritability associated 
with autistic disorder in pediatric patients (ages 6 to 17 years); 2009. 
Available from: http://news.bms.com/press-release/rd-news/us-food- 
and-drug-administration-approves-abilify-aripiprazole-treatment- 
irrita. Accessed January 28, 2015.
14. Kent JM, Kushner S, Ning X, et al. Risperidone dosing in children 
and adolescents with autistic disorder: A double-blind, 
placebo-controlled study. J Autism Dev Disord. 2013;43 
(8):1773–1783. doi:10.1007/s10803-012-1723-5
15. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of 
irritability in children and adolescents with autistic disorder. 
Pediatrics. 2009;124(6):1533–1540. doi:10.1542/peds.2008-3782
16. Fung LK, Mahajan R, Nozzolillo A, et al. Pharmacologic treatment 
of severe irritability and problem behaviors in autism: A systematic 
review and meta-analysis. Pediatrics. 2016;137(Suppl 2):S124–135. 
doi:10.1542/peds.2015-2851K
17. Politte LC, McDougle CJ. Atypical antipsychotics in the treatment of 
children and adolescents with pervasive developmental disorders. 
Psychopharmacology. 2014;231(6):1023–1036. doi:10.1007/s00213- 
013-3068-y
18. Anagnostou E, Aman MG, Handen BL, et al. Metformin for treat-
ment of overweight induced by atypical antipsychotic medication in 
young people with autism spectrum disorder: A randomized clinical 
trial. JAMA Psychiatry. 2016;73(9):928–937. doi:10.1001/jamapsy-
chiatry. 
2016.1232
19. Sturman N, Deckx L, van Driel ML. Methylphenidate for children 
and adolescents with autism spectrum disorder. Cochrane Database 
Syst Rev. 2017;11(11):CD011144.
20. Handen BL, Aman MG, Arnold LE, et al. Atomoxetine, parent 
training, and their combination in children with autism spectrum 
disorder and attention-deficit/hyperactivity disorder. J Am Acad 
Child Adolesc Psychiatry. 2015;54(11):905–915. doi:10.1016/j.jaac. 
2015.08.013
21. Scahill L, McCracken JT, King BH, et al. Extended-release guanfacine for 
hyperactivity in children with autism spectrum disorder. Am J Psychiatry. 
2015;172(12):1197–1206. doi:10.1176/appi.ajp.2015.15010055
22. Ng QX. A systematic review of the use of bupropion for 
attention-deficit/hyperactivity disorder in children and adolescents. 
J Child Adolesc Psychopharmacol. 2017;27(2):112–116. doi:10.10 
89/cap.2016.0124
23. Busner J, Targum SD. The clinical global impressions scale: applying 
a research tool in clinical practice. Psychiatry. 2007;4(7):28–37.
24. Dawkins T, Meyer AT, Van Bourgondien ME. The relationship 
between the childhood autism rating scale: second edition and clin-
ical diagnosis utilizing the DSM-IV-TR and the DSM-5. J Autism 
Dev Discord. 2016;46(10):3361–3368. doi:10.1007/s10803-016- 
2860-z
25. Schopler E, Van Bourgondien ME, Wellman GJ, Love SR. Childhood 
Autism Rating Scale. 2nd ed. Los Angeles, CA: Western 
Psychological Services; 2010.
26. Yilmaz S, Serdaroglu G, Akcay A, Gokben S. Clinical characteristics 
and outcome of children with electrical status epilepticus during slow 
wave sleep. J Pediatr Neurosci. 2014;9(2):105–109. doi:10.4103/ 
1817-1745.139266
27. Hergüner MO, Incecik F, Altunbaşak S, Kiriş N. Clinical character-
istics of 10 patients with continuous spikes and waves during slow 
sleep syndrome. Pediatr Neurol. 2008;38(6):411–414. doi:10.1016/j. 
pediatrneurol.2008.02.007
28. Brian JA, Zwaigenbaum L, Ip A. Standards of diagnostic assessment 
for autism spectrum disorder. Paediatr Child Health. 2019;24 
(7):444–551. doi:10.1093/pch/pxz117
29. Nachshen J, Garcin N, Moxness K, et al. Screening, Assessment, and 
Diagnosis of Autism Spectrum Disorders in Young Children: 
Canadian Best Practice Guidelines. Montreal, Quebec: Miriam 
Foundation; 2008.
30. American Diabetes Association, American Psychiatric Association, 
American Association of Clinical Endocrinologists, North American 
Association for the Study of Obesity. Consensus development con-
ference on antipsychotic drugs and obesity and diabetes. Diabetes 
Care. 2004;27(2):596–601. doi:10.2337/diacare.27.2.596
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                   
Neuropsychiatric Disease and Treatment 2020:16 2792
Alsayouf et al                                                                                                                                                         Dovepress
 
N
eu
ro
ps
yc
hi
at
ric
 D
is
ea
se
 a
nd
 T
re
at
m
en
t d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
16
3.
8.
76
 o
n 
22
-N
ov
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
31. Ho J, Panagiotopoulos C, McCrindle B. for Canadian Alliance for 
Monitoring Effectiveness and Safety of Antipsychotics in Children 
(CAMESA) guideline group. Management recommendations for 
metabolic complications associated with second generation antipsy-
chotic use in children and youth. Paediatr Child Health. 2011;16 
(9):575–580.
32. Kimura G, Kadoyama K, Brown JB, et al. Antipsychotics-associated 
serious adverse events in children: an analysis of the FAERS database. 
Int J Med Sci. 2015;12(2):135–140. doi:10.7150/ijms.10453
33. Roke Y, van Harten PN, Boot AM, Buitelaar JK. Antipsychotic 
medication in children and adolescents: A descriptive review of the 
effects on prolactin level and associated side effects. J Child Adolesc 
Psychopharmacol. 2009;19(4):403–414. doi:10.1089/cap.2008.0120
34. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: 
mechanisms, clinical features and management. Drugs. 2004;64 
(20):2291–2314. doi:10.2165/00003495-200464200-00003
35. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, 
Malhotra AK. Cardiometabolic risk of second-generation antipsycho-
tic medications during first-time use in children and adolescents. 
JAMA. 2009;302(16):1765–1773. doi:10.1001/jama.2009.1549
36. Jensen KG, Juul K, Fink-Jensen A, Correll CU, Pagsberg AK. 
Corrected QT changes during antipsychotic treatment of children 
and adolescents: A systematic review and meta-analysis of clinical 
trials. J Am Acad Child Adolesc Psychiatry. 2015;54(1):25–36. 
doi:10.1016/j.jaac.2014.10.002
37. Rizzo R, Gulisano M, Cali PV, Di Pino A. Mandatory electrocardio-
graphic monitoring in young patients treated with psychoactive 
drugs. Eur Child Adolesc Psychiatry. 2013;22(9):577–579. doi:10.10 
07/s00787-013-0413-y
38. Hashemi E, Ariza J, Rogers H, Noctor SC, Martínez-Cerdeño V. The 
number of parvalbumin-expressing interneurons is decreased in the 
prefrontal cortex in autism. Cereb Cortex. 2017;27(3):1931–1943.
39. Camacho J, Ejaz E, Ariza J, Noctor SC, Martínez-Cerdeño V. RELN- 
expressing neuron density in layer I of the superior temporal lobe is 
similar in human brains with autism and in age-matched controls. 
Neurosci Lett. 2014;579:163–167. doi:10.1016/j.neulet.2014.07.031
40. Nair A, Treiber JM, Shukla DK, Shih P, Müller RA. Impaired 
thalamocortical connectivity in autism spectrum disorder: A study 
of functional and anatomical connectivity. Brain. 2013;136(Pt 
6):1942–1955. doi:10.1093/brain/awt079
41. Cheon KA, Kim YS, Oh SH, et al. Involvement of the anterior 
thalamic radiation in boys with high functioning autism spectrum 
disorders: A diffusion tensor imaging study. Brain Res. 
2011;1417:77–86. doi:10.1016/j.brainres.2011.08.020
42. Testa-Silva G, Loebel A, Giugliano M, de Kock CP, Mansvelder HD, 
Meredith RM. Hyperconnectivity and slow synapses during early 
development of medial prefrontal cortex in a mouse model for mental 
retardation and autism. Cereb Cortex. 2012;22(6):1333–1342. doi:10. 
1093/cercor/bhr224
43. Rinaldi T, Perrodin C, Markram H. Hyper-connectivity and 
hyper-plasticity in the medial prefrontal cortex in the valproic acid 
animal model of autism. Front Neural Circuits. 2008;2:4. doi:10. 
3389/neuro.04.004.2008
44. Kalmbach BE, Johnston D, Brager DH. Cell-type specific channelo-
pathies in the prefrontal cortex of the fmr1-/y mouse model of fragile 
X syndrome. eNeuro. 2015;2(6):ENEURO.0114–15.2015. doi:10.15 
23/ENEURO.0114-15.2015
45. Brumback AC, Ellwood IT, Kjaerby C, et al. Identifying specific 
prefrontal neurons that contribute to autism-associated abnormalities 
in physiology and social behavior. Mol Psychiatry. 2018;23 
(10):2078–2089. doi:10.1038/mp.2017.213
46. Aman M, Rettiganti M, Nagaraja HN, et al. Tolerability, safety, and 
benefits of risperidone in children and adolescents with autism: 
21-month follow-up after 8-week placebo-controlled trial. J Child 
Adolesc Psychopharmacol. 2015;25(6):482–493. doi:10.1089/cap.20 
15.0005
47. Hara Y, Ago Y, Taruta A, et al. Risperidone and aripiprazole alleviate 
prenatal valproic acid-induced abnormalities in behaviors and den-
dritic spine density in mice. Psychopharmacology. 2017;234(21):32 
17–3228. doi:10.1007/s00213-017-4703-9
48. Hara Y, Ago Y, Taruta A, et al. Improvement by methylphenidate and 
atomoxetine of social interaction deficits and recognition memory 
impairment in a mouse model of valproic acid-induced autism. 
Autism Res. 2016;9(9):926–939. doi:10.1002/aur.1596
49. Amendah D, Grosse SD, Peacock G, Mandell DS. The economic 
costs of autism: A review. In: Amaral D, Geschwind D, Dawson G, 
editors. Autism Spectrum Disorders. Oxford: Oxford University 
Press; 2011:1347–1360.
50. Buescher AV, Cidav Z, Knapp M, Mandell DS. Costs of autism 
spectrum disorders in the United Kingdom and the United States. 
JAMA Pediatr. 2014;168(8):721–778. doi:10.1001/jamapediatrics. 
2014.210
51. Autism Speaks. New research finds annual cost of autism has more 
than tripled to $126 billion in the U.S. and reached £34 billion in the 
U.K; 2012. Available from: https://www.autismspeaks.org/press- 
release/new-research-finds-annual-cost-autism-has-more-tripled-126- 
billion-us-and-reached. Accessed April 6, 2020.
52. Lamberti M, Siracusano R, Italiano D, et al. Head-to-head compar-
ison of aripiprazole and risperidone in the treatment of ADHD 
symptoms in children with autistic spectrum disorder and ADHD: 
A pilot, open-label, randomized controlled study. Pediatr Drugs. 
2016;18(4):319–329. doi:10.1007/s40272-016-0183-3
53. Gencer O, Emiroglu FN, Miral S, Baykara B, Baykara A, Dirik E. 
Comparison of long-term efficacy and safety of risperidone and 
haloperidol in children and adolescents with autistic disorder. An 
open label maintenance study. Eur Child Adolesc Psychiatry. 
2008;17(4):217–225. doi:10.1007/s00787-007-0656-6
54. Scahill L, McDougle CJ, Aman MG, et al. Effects of risperidone and 
parent training on adaptive functioning in children with pervasive 
developmental disorders and serious behavioral problems. J Am Acad 
Child Adolesc Psychiatry. 2012;51(2):136–146. doi:10.1016/j.jaac.20 
11.11.010
55. Akhondzadeh S, Fallah J, Mohammadi MR, et al. Double-blind 
placebo-controlled trial of pentoxifylline added to risperidone: 
effects on aberrant behavior in children with autism. Prog 
Neuropsychopharmacol Biol Psychiatry. 2010;34(1):32–36. doi:10. 
1016/j.pnpbp.2009.09.012
56. McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core 
symptom domains of autism: results from the study by the autism 
network of the research units on pediatric psychopharmacology. Am 
J Psychiatry. 2005;162(2):1142–1148. doi:10.1176/appi.ajp.162.6. 
1142
57. Ghaeli P, Nikvarz N, Alaghband-Rad J, Alimadadi A, Tehrani-Doost 
M. Effects of risperidone on core symptoms of autistic disorder based 
on childhood autism rating scale: an open label study. Indian 
J Psychol Med. 2014;36(1):66–70.
58. Williams SK, Scahill L, Vitiello B, et al. Risperidone and adaptive 
behavior in children with autism. J Am Acad Child Adolesc 
Psychiatry. 2006;45(4):431–439. doi:10.1097/01.chi.0000196423.80 
717.32
59. Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of 
risperidone in children with autism spectrum disorders: a placebo 
discontinuation study. J Am Acad Child Adolesc Psychiatry. 
2005;44(11):1137–1144. doi:10.1097/01.chi.0000177055.11229.76
60. Mazurek MO, Lu F, Macklin EA, Handen BL. Factors associated 
with DSM-5 severity level ratings for autism spectrum disorder. 
Autism. 2019;23(2):468–476. doi:10.1177/1362361318755318
61. Brugha TS, Doos L, Tempier A, Howlin P. Outcome measures in 
intervention trials for adults with autism spectrum disorders; 
a systematic review of assessments of core autism features and 
associated emotional and behavioural problems. Int J Methods 
Psychiatr Res. 2015;24(2):99–115. doi:10.1002/mpr.1466
Neuropsychiatric Disease and Treatment 2020:16                                                                       submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                       
2793
Dovepress                                                                                                                                                        Alsayouf et al
 
N
eu
ro
ps
yc
hi
at
ric
 D
is
ea
se
 a
nd
 T
re
at
m
en
t d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
16
3.
8.
76
 o
n 
22
-N
ov
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
62. Lòpez-de Fede A, Vyavaharkar M, Bellinger JD. Antipsychotic pre-
scriptions for children aged 5 years or younger: do we need policy 
oversight standards? SAGE Open. 2014;4(4):1–7. doi:10.1177/ 
2158244014555116
63. Chirdkiatgumchai V, Xiao H, Fredstrom BK, et al. National trends in 
psychotropic medication use in young children: 1994–2009. 
Pediatrics. 2013;132(4):615–623. doi:10.1542/peds.2013-1546
64. Pringsheim T, Stewart DG, Chan P, Tehrani A, Patten SB. The 
pharmacoepidemiology of psychotropic medication use in Canadian 
children from 2012 to 2016. J Child Adolesc Psychopharmacol. 
2019;29(10):740–745. doi:10.1089/cap.2019.0018
65. Fanton J, Gleason MM. Psychopharmacology and preschoolers: 
A critical review of current conditions. Child Adolesc Psychiatr 
Clin N Am. 2009;18(3):753–771. doi:10.1016/j.chc.2009.02.005
66. Gleason MM, Egger HL, Emslie GJ, et al. Psychopharmacological 
treatment for very young children: contexts and guidelines. J Am 
Acad Child Adolesc Psychiatry. 2007;46(12):1532–1572. doi:10.10 
97/chi.0b013e3181570d9e
67. Brophy S, Kennedy J, Fernandez-Gutierrez F, et al. Characteristics of 
children prescribed antipsychotics: analysis of routinely collected 
data. J Child Adolesc Psychopharmacol. 2018;28(3):180–191. doi:10. 
1089/cap.2017.0003
68. Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool 
children with autistic spectrum disorders: an investigation of safety 
and efficacy. J Child Adolesc Psychopharmacol. 2006;16(5):57 
5–587. doi:10.1089/cap.2006.16.575
69. Hossain MM, Khan N, Sultana A, et al. Prevalence of comorbid 
psychiatric disorders among people with autism spectrum disorder: 
an umbrella review of systematic reviews and meta-analyses. 
Psychiatry Res. 2020;287:112922. doi:10.1016/j.psychres.2020.11 
2922
70. Lai MC, Kassee C, Besney R, et al. Prevalence of co-occurring 
mental health diagnoses in the autism population: a systematic review 
and meta-analysis. Lancet Psychiatry. 2019;6(10):819–829. doi:10.10 
16/S2215-0366(19)30289-5
71. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: 
randomized, placebo-controlled, double-blind study. J Child Neurol. 
2006;21(6):450–455. doi:10.1177/08830738060210060801
72. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, 
Price LH. A double-blind, placebo-controlled study of risperidone 
in adults with autistic disorder and other pervasive developmental 
disorders. Arch Gen Psychiatry. 1998;55(7):633–641. doi:10.1001/ 
archpsyc.55.7.633
73. Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone 
improves behavioral symptoms in children with autism in 
a randomized, double-blind, placebo-controlled trial. J Autism Dev 
Disord. 2007;37(2):367–373. doi:10.1007/s10803-006-0234-7
74. Aman MG, Hollway JA, McDougle CJ, et al. Cognitive effects of 
risperidone in children with autism and irritable behavior. J Child 
Adolesc Psychopharmacol. 2008;18(3):227–236. doi:10.1089/cap.20 
07.0133
75. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of 
disruptive behavioral symptoms in children with autistic and other 
pervasive developmental disorders. Pediatrics. 2004;114(5):e634– 
641. doi:10.1542/peds.2003-0264-F
76. Ichikawa H, Mikami K, Okada T, et al. Aripiprazole in the treatment 
of irritability in children and adolescents with autism spectrum dis-
order in Japan: A randomized, double-blind, placebo-controlled 
study. Child Psychiatry Hum Dev. 2017;48(5):796–806. doi:10.10 
07/s10578-016-0704-x
77. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, 
fixed-dose study of aripiprazole in children and adolescents with 
irritability associated with autistic disorder. J Am Acad Child 
Adolesc Psychiatry. 2009;48(11):1110–1119. doi:10.1097/CHI.0b01 
3e3181b76658
78. Finding RL, Mankoski R, Timko K, et al. A randomized controlled 
trial investigating the safety and efficacy of aripiprazole in the 
long-term maintenance treatment of pediatric patients with irritability 
associated with autistic disorder. J Clin Psychiatry. 2014;75 
(1):22–30. doi:10.4088/JCP.13m08500
Neuropsychiatric Disease and Treatment                                                                                          Dovepress 
Publish your work in this journal 
Neuropsychiatric Disease and Treatment is an international, peer- 
reviewed journal of clinical therapeutics and pharmacology focusing 
on concise rapid reporting of clinical or pre-clinical studies on a 
range of neuropsychiatric and neurological disorders. This journal is 
indexed on PubMed Central, the ‘PsycINFO’ database and CAS, and 
is the official journal of The International Neuropsychiatric 
Association (INA). The manuscript management system is comple-
tely online and includes a very quick and fair peer-review system, 
which is all easy to use. Visit http://www.dovepress.com/testimo-
nials.php to read real quotes from published authors.  
Submit your manuscript here: https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                   
Neuropsychiatric Disease and Treatment 2020:16 2794
Alsayouf et al                                                                                                                                                         Dovepress
 
N
eu
ro
ps
yc
hi
at
ric
 D
is
ea
se
 a
nd
 T
re
at
m
en
t d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
16
3.
8.
76
 o
n 
22
-N
ov
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
